Alto Ingredients, Inc.
No enriched coverage for $ALTO in the last 7 days.
No SEC Form 4 filings for $ALTO in the last 30 days.
U.S. stock futures were down on Thursday, with several companies experiencing significant drops in pre-market trading. Alto Neuroscience shares fell 13.6% after its Phase 2 clinical trial did not meet statistical significance. Immunovant Inc. also saw an 8.3% decline following the announcement of its Phase 3 study results.
This article identifies Alto Ingredients (NASDAQ: ALTO), CF Industries Holdings (NYSE: CF), and CVR Partners (NYSE: UAN) as three materials stocks that are currently overbought, according to the Relative Strength Index (RSI). The RSI, a momentum indicator, shows these stocks have values above 70, signaling potential short-term weakness, despite recent positive news or strong performance for some of them. Investors are cautioned to consider this when evaluating their trading decisions in the materials sector.
Alto Ingredients, Inc. (NASDAQ:ALTO) reported strong Q4 and full-year 2025 results, demonstrating significant improvements in earnings and adjusted EBITDA due to increased crush margins, 45Z credits, and renewable fuel export sales. The company achieved a net income of $21.5 million for Q4 2025 and $12.1 million for the full year, a substantial increase from the previous year. Alto Ingredients plans to continue focusing on operational excellence, cost discipline, and strategic investments in 2026, including increasing production capacity at its Pekin Dry Mill and expanding CO2 utilization.
